US Stocks
Jounce Therapeutics Inc
Jounce Therapeutics Inc

Jounce Therapeutics Inc (JNCE)


  • $







Key Stats

Today Low/High$6.1 / $6.4
52 Week Low/High$5.03 / $14.84
Market Cap$332.57M

Company Details

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce's highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce's internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce's most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce's broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc.
OrganisationJounce Therapeutics Inc
HeadquatersCambridge, Massachusetts, US
IndustryHealth Technology
CEORichard Murray

Discover more

Frequently Asked Questions

What is Jounce Therapeutics Inc (JNCE) share price today?

Can Indians buy Jounce Therapeutics Inc (JNCE) shares?

How can I buy Jounce Therapeutics Inc (JNCE) shares from India?

Can Fractional shares of Jounce Therapeutics Inc (JNCE) be purchased?

What are the documents required to start investing in Jounce Therapeutics Inc (JNCE) stocks?